SMYD3 and breast cancer: The overexpressed SMYD3 transcriptionally up-regulated the expression of IGF-1R, through which the AKT/mTOR pathway was activated in BC cells, while the AKT downstream effector E2F1 further enhanced SMYD3 transcription.